| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Aug 7, 2025 | SRK Capital | - | 46.9% | ICCC, ISSC, SLSN, SNWV | asymmetry, catalysts, Concentration, margin expansion, Operating Leverage | The commentary emphasizes concentrated, high-conviction investing with significant upside skew driven by operational inflection points. Management highlights margin expansion, operating leverage, and optionality from regulatory or product catalysts. Cash levels are adjusted dynamically as valuations change. | SNWV SLSN ICCC ISSC |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Jan 8, 2026 | Fund Letters | Sean Kirkwood | ImmuCell Corporation | Health Care | Biotechnology | Bull | NASDAQ | biotechnology, earnings, FDA, Margins, Optionality, Smallcap, Veterinary | View Pitch |
| Jan 8, 2026 | Substack | The Mikrokap | None | Healthcare | Medical Devices | Bull | competitive edge, Core Business, FDA approval, growth potential, market presence, operational efficiency, profitability, Regulatory Risks, shareholder value, Strategic refocus | View Pitch | |
| Sep 20, 2025 | Substack | Just a Value Investor | ImmuCell Corporation | Healthcare | Biotechnology | Bull | Animal Health, calf-level market, contamination issues, FDA approval, First Defense, ImmuCell Corporation, market share, production capacity, Re-Tain, subclinical mastitis | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||